SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutic...

Full description

Saved in:
Bibliographic Details
Main Authors PENG, Yong, LIU, Xijie, LIU, Mei, HAN, Yongxin, WANG, Shulong, HU, Yuandong, CHEN, Kuncheng, LIU, Bo, WANG, Shanchun, XU, Hongjiang, LUO, Hong
Format Patent
LanguageEnglish
French
German
Published 09.03.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
AbstractList The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
Author LUO, Hong
HAN, Yongxin
LIU, Xijie
LIU, Mei
LIU, Bo
HU, Yuandong
XU, Hongjiang
CHEN, Kuncheng
PENG, Yong
WANG, Shanchun
WANG, Shulong
Author_xml – fullname: PENG, Yong
– fullname: LIU, Xijie
– fullname: LIU, Mei
– fullname: HAN, Yongxin
– fullname: WANG, Shulong
– fullname: HU, Yuandong
– fullname: CHEN, Kuncheng
– fullname: LIU, Bo
– fullname: WANG, Shanchun
– fullname: XU, Hongjiang
– fullname: LUO, Hong
BookMark eNqNyr0OgjAUQOEOOvj3DvcBdDAQnEt7kRuhbdrbwYkQU10MkOD7RwYfwOk7w9mK1TAOaSNeIZaBiSOjBnf33jZ2gVrSZBCUvgGZmkpi64_gaulbqTAyKdmAsq2zgZisWdqwJEPmCkG2CNJoiAGBa_Roq71YP_v3nA4_dwIqZFWf0jR2aZ76RxrSp0OX5VleXIrynP2xfAFPYjdj
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate SUBSTITUIERTE PYRROLOPYRIMIDIN-CDK-HEMMER, PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT UND VERWENDUNG DAVON
INHIBITEUR DE CDK PYRROLOPYRIMIDINE SUBSTITUÉE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT ET SON UTILISATION
ExternalDocumentID EP3434676B1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP3434676B13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:59:23 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP3434676B13
Notes Application Number: EP20170769492
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220309&DB=EPODOC&CC=EP&NR=3434676B1
ParticipantIDs epo_espacenet_EP3434676B1
PublicationCentury 2000
PublicationDate 20220309
PublicationDateYYYYMMDD 2022-03-09
PublicationDate_xml – month: 03
  year: 2022
  text: 20220309
  day: 09
PublicationDecade 2020
PublicationYear 2022
RelatedCompanies Lianyungang Runzhong Pharmaceutical Co., Ltd
Centaurus BioPharma Co., Ltd
Chia Tai Tianqing Pharmaceutical Group Co., Ltd
RelatedCompanies_xml – name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd
– name: Lianyungang Runzhong Pharmaceutical Co., Ltd
– name: Centaurus BioPharma Co., Ltd
Score 3.392388
Snippet The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title SUBSTITUTED PYRROLOPYRIMIDINE CDK INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220309&DB=EPODOC&locale=&CC=EP&NR=3434676B1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3PT8IwFG4IGvWmqBF_pQezk0QZ2xgHYrauc1XXLltn8ES2MQwXIDLjv-_rAuhFT31pk5f2Je97fa_tV4RuJoWpWE-mkJZAbmIUZdHJ7azbybPSyKZ60e_mqt4RcitIjaeROWqg2eYtTM0T-lWTI4JHFeDvVY3Xy58illffrVzd5TPoWjz4cuhp6-xY19WJgea5QxoJTxCNEJA0HgNY9wASLBcSpR21i1Y0-_TVVY9Slr8jin-IdiNQNq-OUKOct9A-2Xy81kJ74fq8G8S1662O0XuSuolkMgWowdFbHIsXAQ1gj8c4xcR7xowHzGVSxLc4Cpw4dAhNpeI7wESEkUiYKkeBzKXDOOOPOHFCih3u4TShWAY0psI_QdinkgQdmPF4a50xjbZr652i5nwxL88QtgrTnuqG3b23B8bAsvPCzsp-1jcngLR2z2qj9p9qzv8Zu0AHysz1LazBJWpWH5_lFYTlKr-uDfoNqM-Kdg
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEG8IGvFNUSN-9sHsSaKMffFAzNZ1rsK6ZesMPpFtDMPLIDLjv-9tAfRFn3ppk0t7yf0uv2vvitDdLFOrridzoCXATZQsz7qpkfS6aZIryVzO9F5a5Ts8rrmx8jJRJw202NbC1H1Cv-rmiOBRGfh7WeP16ieJZddvK9cP6QKmlk-OGNrShh3LcnVjINnWkAa-7ROJEJAkHgJY9wESNAuI0p4OjLBmSq9WVZSy-h1RnCO0H4CyojxGjbxooxbZfrzWRgfe5r4bxI3rrU_QexRbkWAiBqjBwVsY-mMfBsAem3GKiT3CjLvMYsIP73HgmqFnEhqLqt8BJr4X-BGr0lEgc2EyzvgzjkyPYpPbOI4oFi4Nqe-cIuxQQdwu7Hi6s86UBruz9c9Qs1gW-TnCWqYac1kxeo_GQBloRpoZSa4nujoDpDX6Wgd1_lRz8c_aLWq5whtPx4yPLtFhZfL6RdbgCjXLj8_8GkJ0md7Uxv0GR4SNYA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=SUBSTITUTED+PYRROLOPYRIMIDINE+CDK+INHIBITOR%2C+PHARMACEUTICAL+COMPOSITION+CONTAINING+SAME+AND+USE+THEREOF&rft.inventor=PENG%2C+Yong&rft.inventor=LIU%2C+Xijie&rft.inventor=LIU%2C+Mei&rft.inventor=HAN%2C+Yongxin&rft.inventor=WANG%2C+Shulong&rft.inventor=HU%2C+Yuandong&rft.inventor=CHEN%2C+Kuncheng&rft.inventor=LIU%2C+Bo&rft.inventor=WANG%2C+Shanchun&rft.inventor=XU%2C+Hongjiang&rft.inventor=LUO%2C+Hong&rft.date=2022-03-09&rft.externalDBID=B1&rft.externalDocID=EP3434676B1